Olaparib for the Treatment of Castration Resistant Prostate Adenocarcinoma

NCT04951492 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

2

Enrollment

OTHER

Sponsor class

Stopped Withdrawal of funding

Conditions

Castration-Resistant Prostate Carcinoma
Prostate Adenocarcinoma

Interventions

DRUG: Olaparib

Sponsor

University of Washington

Collaborators

[object Object]